STEM-01. SHARED ASTROCYTE-LIKE GLIOMA STEM CELLS DRIVE HETEROGENEITY AND IMMUNE DYNAMICS IN ADULT-TYPE DIFFUSE GLIOMAS
Zaman A, Muskovic W, Holton E, Pandya M, Zekanovic R, Chin V, Lam E, Moutinho C, Yeung J, Teo C, Sughrue M, Powell J. STEM-01. SHARED ASTROCYTE-LIKE GLIOMA STEM CELLS DRIVE HETEROGENEITY AND IMMUNE DYNAMICS IN ADULT-TYPE DIFFUSE GLIOMAS. Neuro-Oncology 2024, 26: viii57-viii57. PMCID: PMC11553898, DOI: 10.1093/neuonc/noae165.0227.Peer-Reviewed Original ResearchAdult-type diffuse gliomasGlioma stem cellsT cellsGlioma subtypesGlioma heterogeneityImmune landscapeDiffuse gliomasIDH mutant astrocytomaStem cellsTransform treatment strategiesMyeloid cell infiltrationT cell dysfunctionIDH-mutant gliomasMalignant cell statesAdult neural stem cellsGlioma cell populationsNeural stem cellsSingle surgeryTargeted therapyPoor prognosisCell infiltrationPARD6GTreatment strategiesGene expression profilesTreatment challengesKS01.5.A A BRAIN CANCER CELL ATLAS REVEALS SHARED ASTROCYTE-LIKE STEM CELL STATES DRIVE INTRATUMOURAL HETEROGENEITY AND SHAPE IMMUNE DYNAMICS IN ADULT-TYPE DIFFUSE GLIOMAS
Zaman A, Muskovic W, Holton E, Pandya M, Zakanovic R, Chin V, Lam E, Yeung J, Sughrue M, Teo C, Powell J. KS01.5.A A BRAIN CANCER CELL ATLAS REVEALS SHARED ASTROCYTE-LIKE STEM CELL STATES DRIVE INTRATUMOURAL HETEROGENEITY AND SHAPE IMMUNE DYNAMICS IN ADULT-TYPE DIFFUSE GLIOMAS. Neuro-Oncology 2024, 26: v3-v3. PMCID: PMC11485529, DOI: 10.1093/neuonc/noae144.007.Peer-Reviewed Original ResearchAdult-type diffuse gliomasGlioma stem cellsGlioma heterogeneityGlioma subtypesImmune landscapeDiffuse gliomasT cellsStem cellsTransform treatment strategiesMyeloid cell infiltrationT cell dysfunctionIDH-mutant gliomasMalignant cell populationMalignant cell statesAdult neural stem cellsCell statesPhylogeny-based approachNeural stem cellsSingle surgeryTargeted therapyMyeloid cellsIntratumour heterogeneityCell infiltrationPARD6GTreatment strategiesKeep It Moving: Physical Activity in the Prevention of Obesity-Driven Pancreatic Cancer.
Sogunro A, Muzumdar M. Keep It Moving: Physical Activity in the Prevention of Obesity-Driven Pancreatic Cancer. Cancer Research 2024, 84: 2935-2937. PMID: 39279380, DOI: 10.1158/0008-5472.can-24-1474.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaTumor microenvironmentAntitumor effectPancreatic cancerObese micePhysical activityAdvanced tumor growthSystemic cytokine productionMyeloid cell infiltrationPancreatic ductal adenocarcinoma developmentEffect of obesityHigh-fat diet-induced obesityDiet-induced obesitySyngeneic allograftsAdvanced tumorsProtumorigenic effectsLean miceWhite adipose tissueCell infiltrationDuctal adenocarcinomaObesity-associatedTumor growthCytokine productionImpact of physical activityInflammatory cytokinesTumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled in the HCRN GU16-260 trial.
El Ahmar N, Matar S, Jegede O, Nabil Laimon Y, Savla V, Bagheri Sheshdeh A, Denize T, Mohanna R, Choueiri T, Catalano P, Braun D, Haas N, Hammers H, Bilen M, Stein M, Sosman J, Wu C, McDermott D, Atkins M, Signoretti S. Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled in the HCRN GU16-260 trial. Journal Of Clinical Oncology 2024, 42: 448-448. DOI: 10.1200/jco.2024.42.4_suppl.448.Peer-Reviewed Original ResearchClear cell renal cell carcinomaProgression-free survivalCD163-positive macrophagesTumor areaNivolumab therapyDensity of CD163-positive cellsCD8+ T cell infiltrationAssociated with progression-free survivalResponse to immune checkpoint inhibitorsAdvanced clear cell renal cell carcinomaAnti-PD-1 therapyTumor-infiltrating myeloid cellsProgression-free survival endpointAssociated with poor outcomesFirst-line nivolumabImmune checkpoint inhibitorsMyeloid cell infiltrationT cell infiltrationCell renal cell carcinomaRenal cell carcinomaPrimary tumor tissuesCD163-positive cellsCheckpoint inhibitorsCox proportional hazardsCell carcinoma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply